Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $80
Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $47 to $80.
Share
Why It Matters
An expert analyst thinks 10x Genomics stock could go higher in price. But they still say the stock is neither clearly good nor bad right now.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.